ExxonMobil and Porsche Expand Motorsports Technology Partnership Into Formula E
ExxonMobil is expanding its global business and technical partnership with Porsche by teaming with the luxury German automaker on its Formula E series car for the 2019 / 2020 season. The new partnership represents ExxonMobil’s first entry into electric motorsports.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190906005023/en/
ExxonMobil is expanding its global business and technical partnership with Porsche by teaming with the luxury German automaker on its Formula E series car for the 2019 / 2020 season. (Photo: Business Wire)
Starting from the first race in Saudi Arabia at the end of this year, ExxonMobil will provide Mobil-branded high-performance electric powertrain fluids to Porsche, developed specifically to meet the specialized demands of electric vehicles.
“Our entry into Formula E with Porsche not only represents an expansion to our successful business relationship, but an expansion of a winning partnership in racing,” said Russ Green, vice president, finished lubricants at ExxonMobil. “As Porsche begins to compete and demonstrate the capabilities of its electric vehicle technology, ExxonMobil is engineering a full suite of Mobil-branded lubricants to help the new Porsche Formula E team build on its legacy of racing success around the world. Motorsport provides the ultimate proving ground to continue to develop high-performance lubricants and fluids.”
Vehicles competing in electric motorsports benefit from high-performance lubricant technology that provides specialized advantages needed for the car’s battery pack including electrical conductivity, cooling capabilities and material compatibility.
“As a key technical partner of more than 20 years, no other lubricant supplier understands the Porsche performance philosophy like ExxonMobil,” said Fritz Enzinger, vice president, Porsche Motorsport. “ExxonMobil has not only been a valuable partner for our commercial business, but an important teammate in our pursuit of wins and championships from Sebring to Le Mans. They were a natural addition to our Formula E team as we enter an exciting new era of racing for Porsche.”
The new technical partnership joins ExxonMobil’s existing roster of global motorsports activities with Porsche including the World Endurance Championships, IMSA WeatherTech SportsCar Championship, Porsche Mobil 1 Supercup, Porsche Carrera Cup and numerous customer racing activities around the world.
About ExxonMobil
ExxonMobil, the largest publicly traded international oil and gas company, uses technology and innovation to help meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is one of the largest refiners and marketers of petroleum products, and its chemical company is one of the largest in the world.
About ExxonMobil in Motorsports
Racing provides ExxonMobil and its lubricants and fuels brands the ultimate testing ground to improve the technology in our range of oil, lubricants and fuels. Each race season, our advanced products go to work to help improve vehicle performance and efficiency. ExxonMobil products serve as the lubricant of choice for many of the world’s top race teams competing in highly demanding motorsports series. The knowledge we gain through these partnerships helps our scientists and engineers push the boundaries in developing cutting-edge technologies.
ExxonMobil remains proud partners with Aston Martin Red Bull Racing, Stewart-Haas Racing in NASCAR’s Sprint Cup Series; Porsche, Bentley and TOYOTA GAZOO Racing in the FIA World Endurance Championship; Corvette Racing, Porsche North America, Lexus and Acura/Caterpillar in the IMSA WeatherTech SportsCar Championship; and numerous teams competing in series around the world.
For more information about ExxonMobil and its brands, visit www.exxonmobil.com or follow us on Twitter www.twitter.com/exxonmobil.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190906005023/en/
Contact information
Media Relations
832-625-4000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom